BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31092444)

  • 1. Usefulness of 18-FDG PET/CT in Detecting Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Yamashita YI; Okabe H; Hayashi H; Imai K; Nakagawa S; Nakao Y; Yusa T; Itoyama R; Yama T; Umesaki N; Arima K; Miyata T; Chikamoto A; Baba H
    Anticancer Res; 2019 May; 39(5):2493-2499. PubMed ID: 31092444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of
    Regenet N; Sauvanet A; Muscari F; Meunier B; Mariette C; Adham M; Moutardier V; Delpero JR; Regimbeau JM; Pessaux P; Paye F; Sa Cunha A; Ansquer C
    J Visc Surg; 2020 Oct; 157(5):387-394. PubMed ID: 32005594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of the utility of 18-FDG PET in the preoperative evaluation of IPMNs and cystic lesions of the pancreas.
    Srinivasan N; Koh YX; Goh BKP
    Surgery; 2019 May; 165(5):929-937. PubMed ID: 30577952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
    Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
    Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
    Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
    Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
    Saito M; Ishihara T; Tada M; Tsuyuguchi T; Mikata R; Sakai Y; Tawada K; Sugiyama H; Kurosawa J; Otsuka M; Uchida Y; Uchiyama K; Miyazaki M; Yokosuka O
    Clin Gastroenterol Hepatol; 2013 Feb; 11(2):181-6. PubMed ID: 23142206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and Prognostic Impact of Neutrophil-to-Lymphocyte Ratio for Intraductal Papillary Mucinous Neoplasms of the Pancreas With High-Grade Dysplasia and Associated Invasive Carcinoma.
    Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Takadate T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Furukawa T; Naitoh T; Unno M
    Pancreas; 2019 Jan; 48(1):99-106. PubMed ID: 30540681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-to-blood pool ratio of 18F-fluorodeoxyglucose-positron emission tomography's standardized uptake value as a useful parameter indicating malignant transformation in pancreatic branch-duct intraductal papillary mucinous neoplasm compared to the international Fukuoka guidelines: a retrospective cohort study from surgical resections.
    Suto H; Ando Y; Matsukawa H; Oshima M; Kamada H; Kobara H; Masaki T; Tanaka K; Norikane T; Nishiyama Y; Hirao T; Kumamoto K; Okano K
    HPB (Oxford); 2024 Feb; 26(2):291-298. PubMed ID: 37951806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoembryonic antigen level in the pancreatic juice is effective in malignancy diagnosis and prediction of future malignant transformation of intraductal papillary mucinous neoplasm of the pancreas.
    Hayakawa H; Fukasawa M; Sato T; Takano S; Kadokura M; Shindo H; Takahashi E; Hirose S; Kawakami S; Fukasawa Y; Maekawa S; Inoue T; Yamaguchi T; Nakayama Y; Kawaida H; Kono H; Mochizuki K; Kondo T; Ichikawa D; Enomoto N
    J Gastroenterol; 2019 Nov; 54(11):1029-1037. PubMed ID: 31111221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm.
    Hong HS; Yun M; Cho A; Choi JY; Kim MJ; Kim KW; Choi YJ; Lee JD
    Clin Nucl Med; 2010 Oct; 35(10):776-9. PubMed ID: 20838285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Static and Dynamic
    Lang M; Spektor AM; Hielscher T; Hoppner J; Glatting FM; Bicu F; Hackert T; Heger U; Pausch T; Gutjahr E; Rathke H; Giesel FL; Kratochwil C; Tjaden C; Haberkorn U; Röhrich M
    J Nucl Med; 2023 Feb; 64(2):244-251. PubMed ID: 35906094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-to-Lymphocyte Ratio as a Predictor of Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    McIntyre CA; Pulvirenti A; Lawrence SA; Seier K; Gonen M; Balachandran VP; Kingham TP; DʼAngelica MI; Drebin JA; Jarnagin WR; Allen PJ
    Pancreas; 2019 Jul; 48(6):832-836. PubMed ID: 31210665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic CT density is an optimal imaging biomarker for earlier detection of malignancy in the pancreas with intraductal papillary mucinous neoplasm.
    Yamada D; Kobayashi S; Takahashi H; Yoshioka T; Iwagami Y; Tomimaru Y; Shigekawa M; Akita H; Noda T; Asaoka T; Gotoh K; Tanemura M; Doki Y; Eguchi H
    Pancreatology; 2022 May; 22(4):488-496. PubMed ID: 35396159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of 18FDG-PET confirmed.
    Baiocchi GL; Bertagna F; Gheza F; Grazioli L; Calanducci D; Giubbini R; Portolani N; Giulini SM
    Ann Surg Oncol; 2012 Oct; 19(11):3574-80. PubMed ID: 22752369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-lymphocyte ratio and mural nodule height as predictive factors for malignant intraductal papillary mucinous neoplasms.
    Watanabe Y; Niina Y; Nishihara K; Okayama T; Tamiya S; Nakano T
    Acta Chir Belg; 2018 Aug; 118(4):239-245. PubMed ID: 29334845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas Showing High Accumulation of 18F-Fluorodeoxyglucose (FDG)--A Case Report].
    Kubota M; Nishimura M; Nakatsuka R; Miyazaki S; Danno K; Motoori M; Matsuda C; Fujitani K; Iwase K
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2394-6. PubMed ID: 26805375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.